哪里想瘦打哪里！FDA批文Kythera注射药物上市在即

你才双下巴，你家中都双下巴！乃是大方之心人皆有之。如果说赘肉是每一个借此具备完美身材高大的“妹纸”或“汉纸”的大敌，那么一个喜感十足的双下巴已是是这些人的究竟仇敌了。每一分钟，世界各地都有人为自己的一张大饼脸而感到烦恼，虽然具备一个肉感十足的双下巴捏上去是挺有肉感的，但是还是有很多人的同龄使其没有施加一个双下巴之重。您可千万别笑，这甚至已经催生显露一个庞大的市场需求。根据美国黏膜麻醉基金会的追查分析标示出，68%的英裔对自己的双下巴声称了“厌倦”之情。而亦然，最近Kythera美国公司向FDA提交了其专门歼灭双下巴的护肤品服用式抑止生素ATX-101。这种抑止生素进行时了许多“胖纸”梦寐以求的特性，哪里想瘦打哪里，已是是定点减肥。不要以为这种近乎冷酷的抑止生素只是一个笑话，在FDA下属的黏膜和耳鼻喉科抑止生素局长会的无记名投票里面，技术人员可是以17：0的超高票数原则上赞同其香港交易所。似乎是因为这些技术人员里面也有很多饱受双下巴之苦吧。FDA也将开发计划于月内的5月13日此前对其跟进最后不得不。如果一切顺利的话，Kythera美国公司开发计划于月内月末将该厂家香港交易所，分析人士下半年这一抑止生素的年销售额将将近3亿美元之多。随着护肤品抑止生素市场需求的日益变大，Kythera美国公司已是是下了一步好棋。美国公司于往年以8400万美元的生产成本从其前合作关系拜耳手里面收回了这种抑止生素的全部权利。而Kythera美国公司也借此用意为自始在护肤品抑止生素市场需求里面攻城拔寨。就在上个月，Kythera美国公司和Actelion美国公司促成价值2700万美元的合作备忘录，联合开发一种失败过的抑止呼吸道抑止生素，而这种抑止生素被认为有可能开发显露一种治疗脱发的抑止生素。详细英语报道：Kythera ($KYTH) won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment.The agency's independent Dermatologic and Ophthalmic Drugs Advisory Committee voted 17-0 that the drug's benefits outweighed its risks for patients looking to reduce submental fat, or double chin. The FDA is not required to follow its panels' votes, though it most commonly does, and the agency has promised to make a final decision on the injection by May 13. If all goes according to plan, Kythera plans to launch the drug, ATX-101, in the second half of this year.The biotech's shares he more than tripled since it pulled off a $73 million IPO in 2012, rising steadily as investors bet ATX-101 can carve out a space on the aesthetic market and potentially lure a Big Pharma acquirer. Kythera is pitching the injection as a much-needed nonsurgical option for double chin reduction, citing an American Society for Dermatologic Surgery survey that estimates 68% of Americans are "bothered" by submental fat.Kythera regained full rights to ATX-101's potential last year, orchestrating an $84 million deal to buy out ex-partner Bayer. And the drug, a synthetic version of the fat-blasting deoxycholic acid, could bring in more than $300 million a year once approved, Leerink yst Seamus Fernandez has said."This milestone demonstrates our commitment to developing first-in-class aesthetic products through a focus on scientific rigor and innovation," Kythera CEO Keith Leonard said in a statement. "At Kythera, we remain focused on investing in novel treatments that will allow aesthetic physicians to better meet the needs of their patients."Kythera is also focused on raising some cash now that it has a likely approval ahead. The biotech filed for a $125 million offering as soon as the market closed on Monday. Its share price was down several points at the end of the day.Beyond its top prospect, Kythera is working to build out a pipeline of aesthetic medicines. Last month, the California biotech signed a $27 million deal with Actelion ($ATLN) to get its hands on a once-failed anti-inflammatory medicine that could he a future as a treatment for hair loss.